Carbon dioxide equivalent emissions and cost impact of non-clinically driven inhaler initiation or switch for COPD
CO<sub>2</sub>e emission savings with non-clinically driven DPI use within the SITT class are offset by increased emissions from poorer clinical control and healthcare use. Prescribing policies/guidelines preferring DPIs over pMDIs for environmental reasons should be updated, recognizing that pMDIs with NGP have a greenhouse gas footprint similar to DPIs. Optimal COPD management through evidence-based guidelines and appropriate inhaler selection is crucial to minimizing carbon footprint and healthcare resource utilization while improving patient outcomes.
Authors
- Richard Fordham (ORCID: https://orcid.org/0000-0002-5520-6255)
- John F. Marshall (ORCID: https://orcid.org/0000-0002-0494-2295)
- Krishnali Parsekar
- Abdelhamid Yousef
- Usmani OS
- Deniz Tansey-Dwyer
- George Agathangelou
- Isabella Rustignoli
- Magnus Köping-Höggård
- Dorthe Petersen
- John P Bell
- Juan Soto
- Georgios Xydopoulos
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of East Anglia (GB)
- Hess (United States) (US)
- AstraZeneca (South Korea) (KR)
- Royal Brompton Hospital (GB)
- AstraZeneca (France) (FR)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Italy) (IT)
- Imperial College London (GB)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1080/03007995.2026.2628120
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00